# ZBED2

## Overview
ZBED2 is a human gene that encodes the zinc finger BED-type containing 2 protein, which is characterized by the presence of BED-type zinc finger domains. These domains are integral to the protein's function as a transcriptional repressor, allowing it to bind DNA and regulate gene expression. The ZBED2 protein plays a crucial role in modulating the interferon response, particularly in epithelial tissues such as the skin, lung, and esophagus, where it acts as a tissue-specific attenuator to protect against chronic inflammation. It is involved in maintaining the basal state of keratinocytes and influencing stem cell functions, thereby impacting tissue homeostasis and identity. ZBED2's expression is notably high in certain epithelial tissues and is implicated in various cancers, including pancreatic ductal adenocarcinoma, where it contributes to disease progression by repressing the interferon response pathway and promoting lineage plasticity (Somerville2019ZBED2).

## Structure
ZBED2 is a human gene encoding a protein characterized by the presence of BED-type zinc finger domains, which are involved in DNA binding and transcriptional regulation. The primary structure of ZBED2 includes amino acid sequences that form these zinc finger motifs, which are crucial for its function as a transcriptional repressor. The protein acts as a sequence-specific repressor, binding to promoter regions of interferon-stimulated genes (ISGs) and inhibiting their expression (Somerville2019ZBED2).

The secondary structure of ZBED2 likely includes alpha helices and beta sheets, typical of proteins with zinc finger domains, although specific details are not provided in the context. The tertiary structure, which refers to the overall 3D shape of the protein, is not detailed in the available sources. Similarly, information on the quaternary structure, which involves the assembly of protein subunits, is not provided.

ZBED2 is known to function as a transcriptional repressor in pancreatic ductal adenocarcinoma, where it antagonizes the interferon response pathway and modulates cell identity (Somerville2019ZBED2). The presence of multiple ZBED2 motifs in promoters is associated with strong genomic occupancy and a stronger repressive effect on transcription (Somerville2019ZBED2).

## Function
ZBED2 is a zinc finger protein that plays a significant role in modulating gene expression, particularly in squamous epithelial tissues such as the skin, lung, and esophageal mucosa. It is suggested to function as a tissue-specific attenuator of the interferon (IFN) response, potentially protecting these tissues from chronic IFN stimulation and inflammation (Somerville2019ZBED2). ZBED2 is involved in regulating keratinocyte differentiation, promoting the basal keratinocyte state, and influencing stem cell functions in epithelial tissues (Somerville2019ZBED2). The protein acts as a transcriptional repressor, modulating the transcriptional output of Interferon Regulatory Factor (IRF) transcription factors, which are crucial in the regulation of the skin epidermis (Somerville2019ZBED2).

In healthy human cells, ZBED2 is expressed in tissues frequently exposed to pathogens, such as the thyroid, esophagus, lung, and skin, suggesting its role in defining thresholds for IFN responsiveness and protecting these tissues from inflammation and damage (Somerville2019ZBED2). The gene's expression is tissue-specific, with high levels in certain epithelial tissues, but it is not detected in the normal human pancreas (Somerville2019ZBED2).

## Clinical Significance
ZBED2 has been implicated in several cancers, particularly pancreatic ductal adenocarcinoma (PDA), where its aberrant expression is associated with poor clinical outcomes. In PDA, ZBED2 acts as an antagonist of Interferon Regulatory Factor 1 (IRF1), modulating cell identity and repressing the interferon response pathway. This repression contributes to the aggressive nature of the disease by promoting lineage plasticity and inhibiting anti-tumor effects (Somerville2019ZBED2). High ZBED2 expression is linked to the squamous subtype of PDA, which is characterized by poorly differentiated tumors and increased invasiveness, correlating with shorter overall survival (Somerville2019ZBED2).

ZBED2 is also expressed in other cancers, such as colorectal and lung cancers, where it is associated with aggressive disease and poor prognosis (Somerville2019ZBED2). The gene's expression is enriched in cancer cell lines with common genetic alterations like KRAS, TP53, CDKN2A, and SMAD4, although it is not essential for cell growth under standard conditions (Somerville2019ZBED2). The presence of ZBED2 in tissues frequently exposed to pathogens suggests a potential evolutionary role in regulating immune responses, which may be co-opted during tumorigenesis to dampen immune signaling (Somerville2019ZBED2).

## Interactions
ZBED2 is a transcriptional repressor that interacts with various proteins and nucleic acids to modulate gene expression. It acts as an antagonist to Interferon Regulatory Factor 1 (IRF1) by co-occupying certain interferon-stimulated gene (ISG) promoters, such as CMPK2 and STAT2, where it functions in an antagonistic manner. ZBED2 reduces IRF1's ability to activate these promoters through competitive DNA binding at specific motifs recognized by both proteins (Somerville2019ZBED2). This interaction highlights ZBED2's role in repressing the transcriptional output of IRF1, thereby modulating the interferon response pathway in pancreatic ductal adenocarcinoma (PDA) cells (Somerville2019ZBED2).

ZBED2 also interacts with the transcription factor FOXA1 in bladder cancer, where their expressions are often mutually exclusive. ZBED2 overexpression leads to FOXA1 downregulation, suggesting a regulatory interaction that may influence cell identity by maintaining either Luminal or Basal phenotypes (NeyretKahn2022Epigenomic). These interactions underscore ZBED2's role in transcriptional regulation and its potential impact on cellular identity and disease progression.


## References


1. (NeyretKahn2022Epigenomic) Epigenomic mapping identifies a super-enhancer repertoire that regulates cell identity in bladder cancers through distinct transcription factor networks. This article has 0 citations.

2. (Somerville2019ZBED2) ZBED2 is an antagonist of Interferon Regulatory Factor 1 and modulates cell identity in pancreatic cancer. This article has 4 citations.